Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA.
Dr Bing Zhang Department of Statistics, University of Kentucky, Lexington, KY.
J Orthop Trauma. 2024 Jul 1;38(7):358-365. doi: 10.1097/BOT.0000000000002807.
To determine whether scheduled low-dose, short-term ketorolac modulates cytokine concentrations in orthopaedic polytrauma patients.
Secondary analysis of a double-blinded, randomized controlled trial.
Single Level I trauma center from August 2018 to October 2022.
Orthopaedic polytrauma patients between 18 and 75 years with a New Injury Severity Score greater than 9 were enrolled. Participants were randomized to receive 15 mg of intravenous ketorolac every 6 hours for up to 5 inpatient days or 2 mL of intravenous saline similarly.
Daily concentrations of prostaglandin E2 and interleukin (IL)-1a, IL-1b, IL-6, and IL-10. Clinical outcomes included hospital and intensive care unit length of stay, pulmonary complications, and acute kidney injury.
Seventy orthopaedic polytrauma patients were enrolled, with 35 participants randomized to the ketorolac group and 35 to the placebo group. The overall IL-10 trend over time was significantly different in the ketorolac group ( P = 0.043). IL-6 was 65.8% higher at enrollment compared to day 3 ( P < 0.001) when aggregated over both groups. There was no significant treatment effect for prostaglandin E2, IL-1a, or IL-1b ( P > 0.05). There were no significant differences in clinical outcomes between groups ( P > 0.05).
Scheduled low-dose, short-term, intravenous ketorolac was associated with significantly different mean trends in IL-10 concentration in orthopaedic polytrauma patients with no significant differences in prostaglandin E2, IL-1a, IL-1b, or IL-6 levels between groups. The treatment did not have an impact on clinical outcomes of hospital or intensive care unit length of stay, pulmonary complications, or acute kidney injury.
Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
确定计划给予低剂量、短期的酮咯酸是否能调节骨科多发创伤患者的细胞因子浓度。
双盲、随机对照试验的二次分析。
2018 年 8 月至 2022 年 10 月的一级创伤中心。
18-75 岁,新损伤严重程度评分大于 9 的骨科多发创伤患者。参与者被随机分配接受 15mg 静脉注射酮咯酸,每 6 小时一次,最多 5 天住院治疗,或类似地接受 2mL 静脉注射生理盐水。
每天的前列腺素 E2 和白细胞介素(IL)-1a、IL-1b、IL-6 和 IL-10 浓度。临床结果包括住院和重症监护病房的住院时间、肺部并发症和急性肾损伤。
共纳入 70 例骨科多发创伤患者,其中 35 例患者被随机分配到酮咯酸组,35 例患者被分配到安慰剂组。酮咯酸组的总体 IL-10 趋势随时间变化明显不同(P=0.043)。当汇总两组数据时,IL-6 在入组时比第 3 天高 65.8%(P<0.001)。前列腺素 E2、IL-1a 或 IL-1b 无显著的治疗效果(P>0.05)。两组间的临床结果无显著差异(P>0.05)。
计划给予低剂量、短期、静脉注射酮咯酸与骨科多发创伤患者的 IL-10 浓度的平均趋势明显不同,但两组间前列腺素 E2、IL-1a、IL-1b 或 IL-6 水平无显著差异。该治疗并未对住院或重症监护病房的住院时间、肺部并发症或急性肾损伤的临床结果产生影响。
治疗性 II 级。有关证据水平的完整说明,请参阅作者说明。